HUMAN CALCIUM CHANNELS ALFA1 SUBUNITS AND RELATED PROBES, CELL LINES AND METHODS

Abstract: Partial sequences for a novel mammalian (human and rat sequences identified) calcium channel subunit which we have labeled as the alpha II subunit, and an additional novel human calcium channel which we have labeled as the alpha IH subunit are provided. Knowledge of the sequence of these two calcium channels permits the localization and recovery of the complete sequence from human cells, and the development of cell lines which express the novel calcium channels of the invention. These cells may be used for identifying compounds capable of acting as agonists or antagonists to the calcium channels.

Description: HUMAN CALCIUM CHANNELS ALFA1 SUBUNITS AND RELATED PROBES. CELL LINES AND METHODS DESCRIPTION TECHNICAL FIELD The present invention relates to novel human calcium channel compositions, and to the expression of these compositions in cell lines for use in evaluating calcium channel function. BACKGROUND OF THE INVENTION The rapid entry of calcium into cells is mediated by a class of proteins called voltage- gated calcium channels. Calcium channels are a heterogeneous class of molecules that respond to depolarization by opening a calcium-selective pore through the plasma membrane. The entry of calcium into cells mediates a wide variety of cellular and physiological responses including excitation-contraction coupling, hormone secretion and gene expression. In neurons, calcium entry directly affects membrane potential and contributes to electrical properties such as excitability, repetitive firing patterns and pacemaker activity. Miller, R.J. (1987) Multiple calcium channels and neuronal function. Science 235:46-52. Calcium entry further affects neuronai functions by directly regulating calcium-dependent ion channels and modulating the activity of calcium-dependent enzymes such as protein kinase C and caimodulin-dependent protein kinase II. An increase in calcium concentration at the presynaptic nerve terminal triggers the release of neurotransmitter. Calcium entry also plays a role in neurite outgrowth and growth cone migration in developing neurons and has been implicated in long-term changes in neuronal activity. In addition to the variety of normal physiological functions mediated by calcium channels, they are also implicated in a number of human disorders. Recently, mutations identified in human and mouse calcium channel genes have been found to account for several disorders including, familial hemiplegic migraine, episodic ataxia type 2. cerebellar ataxia. absence epilepsy and seizures. Fletcher, et al. (1996) Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell 87:607-617; Burgess, et al. ( 1997) Mutation of the Ca2+ channel β subunit gene Cchb4 is associated with ataxia and seizures in the lethargic (lh) mouse. Cell 88:385-392; Ophoff, et al. (1996) Familial hemipiegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1 A4. cell 87:543-552; Zhuchenko, O. et al. (1997) Autosomal dominat cerebellar ataxia (SCA6) associated with the small polyglutamine expansions in the αl A- voltage-dependent calcium channel. Nature Genetics 15:62-69. The clinical treatment of some disorders has been aided by the development of therapeutic calcium channel antagonists. Janis, et al. (1991) In Calcium Channels: Their Properties, Functions, Regulation and Clinical Relevance. CRC Press, London. Native calcium channels have been classified by their electrophysiological and pharmacological properties as T, L, N, P and Q types (for reviews see McCleskey, et al. (1991) Functional properties of voltage-dependent calcium channels. Curr. Topics Membr. 39: 295-326, and Dunlap, et al. (1995) Exocytotic Ca 2+ channels in mammalian central neurons. Trends Neurosci. 18:89-98.). T-type (or low voltage-activated) channels describe a broad class of molecules that transiently activate at negative potentials and are highly sensitive to changes in resting potential. The L, N, P and Q-type channels activate at more positive potentials and display diverse kinetics and voltage-dependent properties. There is some overlap in biophysical properties of the high voltage-activated channels, consequently pharmacological profiles are useful to further distinguish them. L-type channels are sensitive to dihydropyridine (DHP) agonists and antagonists, N-type channels are blocked by the Conus geographus peptide toxin, ω-conotoxin GVIA, and P-type channels are blocked by the peptide ω-agatoxin IVA from the venom of the funnel web spider, Agelenopsis aperta. A fourth type of high voltage-activated Ca channel (Q-type) has been described, although whether the Q- and P-type channels are distinct molecular entities is controversial (Sather et al. (1993) Distinctive biophysical and pharmacological properties of class A (Bl) calcium channel αl subunits. Neuron 11: 291-303; Stea, et al. (1994) Localization and functional properties of a rat brain αl A calcium channel reflect similarities to neuronal Q- and P-type channels. Proc Natl Acad Sci (USA) 91 : 10576-10580.). Several types of calcium conductances do not fall neatly into any of the above categories and there is variability of properties even within a category suggesting that additional calcium channels subtypes remain to be classified. Biochemical analyses show that neuronal calcium channels are heterooligomeric complexes consisting of three distinct subunits (α„ α 2 δ and β)( reveiwed by De Waard. et al. (1997) In Ion Channels. Volume 4. edited by Narahashi, T. Plenum Press, New York). The α, subunit is the major pore-forming subunit and contains the voltage sensor and binding sites for calcium channel antagonists. The mainly extracellular α 2 is disulphide- linked to the transmembrane δ subunit and both are derived from the same gene and are proteoiytically cleaved in vivo. The β subunit is a non-glycosylated, hydrophilic protein with a high affinity of binding to a cytoplasmic region of the α, subunit. A fourth subunit, γ, is unique to L-type Ca channels expressed in skeletal muscle T-tubules. The isolation and characterization of γ-subunit-encoding cDNAs is described in US Patent No. 5,386,025 which is incorporated herein by reference. Molecular cloning has revealed the cDNA and corresponding amino acid sequences of six different types of α, subunits (α 1A , α 1B , α lc , α tD , α 1E and α ls ) and four types of β subunits (β„ β 2 , β 3 and β 4 )(reviewed in Stea, A., Soong, T.W. and Snutch, T.P. (1994) Voltage-gated calcium channels. PCT Patent Publication WO 95/04144, which is incorporated herein by reference, discloses the sequence and expression of α, E calcium channel subunits. In Handbook of Receptors and Channels. Edited by R.A. North, CRC Press.). T e different classes of αl and β subunits have been identified in different animals including, rat, rabbit and human and share a significant degree of amino acid conservation across species (for examples see: Castellano, et al. ( 1993) Cloning and expression of a third calcium channel β subunit. J. Biol. Chem. 268: 3450-3455; Castellano, et al. (1993) Cloning and expression of a neuronal calcium channel β subunit. J. Biol. Chem. 268: 12359- 12366; Dubel, et al. (1992). Molecular cloning of the α, subunit of an ω-conotoxin-sensitive calcium channel. Proc. Natl. Acad. Sci. (USA) 89: 5058-5062; Fujita, et al.. (1993) Primary structure and functional expression of the ω-conotoxin-sensitive N-type calcium channel from rabbit brain. Neuron 10: 585-598; Mikami. et al.. (1989). Primary structure and functional expression of the cardiac dihydropyridine-sensitive calcium channel. Nature 340: 230-233; Mori, et al. (1991) Primary structure and functional expression from complementary DNA of a brain calcium channel. Nature 350: 398-402; Perez-Reyes, et al. (1992). Cloning and expression of a cardiac/brain β subunit of the L-type calcium channel. J. Biol. Chem. 267: 1792-1797; Pragnell. et al. ( 1991 ). Cloning and tissue-specific expression of the brain calcium channel β-subunit. FEBS Lett. 291 : 253-258; Snutch, et al. (1991) Distinct calcium channels are generated by alternative splicing and are differentially expressed in the mammalian CNS. Neuron 7: 45-57; Soong, et al. (1993) Structure and functional expression of a member of the low voltage-activated calcium channel family. Science 260: 1133-1136; Tomlinson, et al. (1993) Functional properties of a neuronal class C L-type channel. Neuropharmacology 32: 11 17-1126; Williams, et al. (1992) Structure and functional expression of αl, α2, and β subunits of a novel human neuronal calcium channel subtype. Neuron 8: 71-84; Williams, et al. (1992) Structure and functional expression of an ω-conotoxin-sensitive human N-type calcium channel. Science 257: 389-395. In some expression systems the α, subunits alone can form functional calcium channels although their electrophysioiogical and pharmacological properties can be differentially modulated by coexpression with any of the four β subunits. Until recently, the reported modulatory affects of β subunit coexpression were to mainly alter kinetic and voltage-dependent properties. More recently it has been shown that β subunits also play crucial roles in modulating channel activity by protein kinase A, protein kinase C and direct G-protein interaction. (Bourinet, et al. (1994) Voltage-dependent facilitation of a neuronal αlC L-type calcium channel. EMBO J. 13: 5032-5039; Stea, et al. (1995) Determinants of PKC-dependent modulation of a family of neuronal calcium channels. Neuron 15:929-940; Bourinet, et al. (1996) Determinants of the G-protein-dependent opioid modulation of neuronal calcium channels. Proc. Natl. Acad. Sci. (USA) 93: 1486-1491.) The electrophysioiogical and pharmacological properties of the calcium channels cloned to date can be summarized as shown in Table 1. While the cloned α, subunits identified to date correspond to several of the calcium channels found in cells, they do not account for all types of calcium conductances described in native cells. For example, they do not account for the various properties described for the heterogenous family described as T-type calcium channels. Furthermore, they do not account for novel calcium channels described in cerebellar granule cells or other types of cells. ( Forti. et al (1993) Functional diversity of L-type calcium channels in rat cerebellar neurons. Neuron 10: 437-450; Tottene.et al. (1996). Functional diversity of P-type and R-type calcium channels in rat cerebellar neurons. J. Neurosci. 16: 6353-6363). Because of the importance of calcium channels in cellular metabolism and human disease, it would be desirable to identify the remaining classes of α, subunits, and to develop expression systems for these subunits which would permit the study and characterization of these calcium channels, including the study of pharmacological modulators of calcium channel function. Thus, it is an object of the present invention to provide heretofor undisclosed calcium channels having novel α, subunits, including cell lines expressing these new calcium channels. It is a further object of the present invention to provide a method for testing these novel calcium channels using such cell lines. SUMMARY OF THE INVENTION The present invention provides partial sequences for a novel mammalian (human and rat sequences identified) calcium channel subunit which we have labeled as the α„ subunit, and an additional novel human calcium channel which we have labeled as the α 1H subunit. This knowledge of the sequence of these two calcium channels permits the localization and recovery of the complete sequence from human cells, and the development of cell lines which express the novel calcium channels of the invention. These cells may be used for identifying compounds capable of acting as agonists or antagonists to the calcium channels. BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 shows aligned amino acid sequences for the C. elegans C54D2.5 α, calcium channel subunit and initially identified portions of the calcium channel subunits of the invention. DESCRIPTION OF THE INVENTION The present invention includes the following aspects for which protection is sought: (a) novel human calcium channel subunits and DNA fragments encoding such subunits. It will be appreciated that polymorphic variations may be made or may exist in the DNA of some individuals leading to minor deviations in the DNA or amino acids sequences from those shown which do not lead to any substantial alteration in the function of the calcium channel. Such variations, including variations which lead to substitutions of amino acids having similar properties are considered to be within the scope of the present invention. (b) poiynucieotide sequences useful as probes in screeriing human cDNA libraries for genes encoding these novel calcium channel subunits. These probes can also be used in histological assay to determine the tissue distribution of the novel calcium channel subunits. (c) eukaryotic cell lines expressing the novel calcium channel subunits. These cell lines can be used to evaluate compounds as pharmacological modifiers of the function of the novel calcium channel subunits. - 7 - (d) a method for evaluating compounds as pharmacological modifiers of the function of the novel calcium channel subunits using the cell lines expressing those subunits alone or in combination with other calcium channel subunits. Further, since defects in the novel calcium channel subunits may be associated with a human genetic disease including, but not limited to; epilepsy, migraine, ataxia, schizophrenia, hypertension, arrhythmia, angina, depression, small lung carcinoma, Lambert- Eaton syndrome, characterization of such associations and ultimately diagnosis of associated diseases can be carried out with probes which bind to the wild-type or defective forms of the novel calcium channels. In accordance with the present invention, we have identified human DNA sequences which code for novel calcium channel α, subunits. These subunits are believed to represent two new types of α, subunits of human voltage-dependent calcium channels which have been designated as type α„ and type α, H . The novel α, subunits of the invention were identified by screening the C. elegans genomic DNA sequence data base for sequences homologous to previously identified mammalian calcium channel α, subunits. Specifically, the following twelve mammalian α, subunit sequences were used to screen the C. elegans genomic data bank: rat brain α, A GTCAAAACTC AGGCCTTCTA CTGG SEQ ID. No. 1 rat brain α IA AACGTGTTCT TGGCTATCGC GGTG SEQ ID. No.2 rat brain α, B GTGAAAGCAC AGAGCTTCTA CTGG SEQ ID. No.3 rat brain α 1B AACGTTTTCT TGGCCATTGC TGTG SEQ ID. No.4 rat brain α, c GTTAAATCCA ACGTCTTCTA CTGG SEQ ID. No. 5 rat brain α, c AATGTGTTCT TGGCCATTGC GGTG SEQ ID. No.6 rat brain α ID GTGAAGTCTG TCACGTTTTA CTGG SEQ ID. No. 7 rat brain α, D AAGCTCTTCT TGGCCATTGC TGTA SEQ ID. No. 8 rat brain α 1E GTCAAGTCGC AAGTGTTCTA CTGG SEQ ID. No. 9 rat brain α IE AATGTATTCT TGGCTATCGC TGTG SEQ ID. No. 10 rat brain consensus #1 : ATCTAYGCYR TSATYGGSAT G SEQ ID. No. 11 rat brain consensus ήl : ATGGACAAYT TYGASTAYTC SEQ ID. No. 12 This search identified four distinct C. elegans cosmids that contain open reading frames (coding regions) that exhibit homology to mammalian calcium channel α, subunits: cosmid and reading frame T02C5.5 cosmid and reading frame C48A7.1 cosmid and reading frame C54D2.5 cosmid and reading frame C27F2.3 Examination of the four C. elegans cosmid sequences by phylogeny analysis shows that two of these, T02C5.5 and C48A7.1, correspond closely with previously identified mammalian α, subunits. T02C5.5 appears to be an ancestral member related to the mammalian α 1A , α, B and α, E subunits. C48A7.1 appears to be an ancestral member related to the mammalian L-type channels encoded by α lc , α, D and α, s . In contrast, the C. elegans cosmids C54D2.5 and C27F2.3 identify novel types of calcium channel α, subunits distinct from the other mammalian subtypes. Mammalian counterparts of the C. elegans calcium channel α, subunit encoded by C54D2.5 were identified by screening of the GenBank expressed sequence tag (EST) data bank. This analysis identified a total of 13 mammalian sequences that exhibit some degree of DNA sequence and amino acid identity to C54D2.5, of which 8 are human sequences. (Table 2) Three of these sequences appear unlikely to encode novel calcium channel subunits because they either exhibit a significant degree of homology to previously identified mammalian α, subunits (clones H06096 and H14053) or exhibit homology in a region not considered to be diagnostic of calcium channel α, subunits specifically as opposed to other types of ion channel molecules in general (clone D20469). The five reπiaining sequences (H55225, H55617, H55223, H55544, and F07776), however, are believed to encode two previously unidentified calcium channel α, subunits because the degree of amino acid identity closely matches that of known calcium channel subunits in conserved regions but is sufficiently different to indicate that they do not encode previously identified mammalian calcium channel , subunits. α IΛ , u ιa , α, c , α, D , α, E , or α, s . The expected amino acid sequence closely matches but is not identical to amino acid sequences in these known calcium channel subunits. The aligned amino acids sequences are shown in Fig 1. Table 2 Query = C54D2.5 CE02562 CALCIUM CHANNEL ALPHA- 1 SUBUNIT LG:6 Database: Non-redundant Database of GenBank EST Division 824,500 sequences; 302,742,428 total letter Sequences producing High-scoring Segment Pairs: Frame Score P(N) gb| AA183990! AA183990 ms53e02.rl Life Tech mouse embry... + 1 108 1.8e-24 gb|H55225|H55225 CHR220164 Homo sapiens genomic c... +1 136 2.5e-10 dbj|D68412|CELK131BlF C.elegans cDNA clone ykl31bl : 5... +3 117 1.7e-06 gb|R75128|R75128 MDB 1075 Mouse brain, Stratagene ... +3 113 7.2e-06 gb|H55617|H55617 CHR220556 Homo sapiens genomic c... +2 102 2.8e-05 emb|F07776|HSC2HD061 H. sapiens partial cDNA sequence... +3 100 0.00057 gb|W76774|W76774 me84e08.rl Soares mouse embryo N... +2 98 0.0012 gb|H06096|H06096 yl77e01.r 1 Homo sapiens cDNA clo... +3 98 0.0015 gb|H14053|H14053 ym65dl0.rl Homo sapiens cDNA clo... +2 91 0.0036 gb|H55223|H55223 CHR220162 Homo sapiens genomic c... +2 87 0.0039 dbj|D35703|CELK024D9F C.elegans cDNA clone yk24d9 : 5'... +3 74 0.046 dbj|D20469|HUMGS01443 Human HL60 3'directed Mbol cDNA,... -2 66 0.91 gb|H55544|H55544 CHR220483 Homo sapiens genomic c... +1 65 0.98 Four of the five sequences (H55225, H55617, H55223, and H55544) are found on human chromosome 22. and are now believed to ail be part of the same gene encoding the novel human calcium channel subunit α„. The fifth sequence. F07776 is apparently distinct and associated with a further novel human calcium channel subunit designated α,„. The sequences of the five selected sequences and the references from which they are taken are given as follows: H55225 SOURCE human clone=C22_207 primer=T3 library=Chromosome 22 exon Trofatter, et al., Genome Res. 5 (3): 214-224 (1995) SEQ ID No. 13 1 GTGATCACTC TGGAAGGCTG GGTGGAGATC ATGTACTACG TGATGGATGC TCACTCCTTC 61 TACAACTTCA TCTACTTCAT CCTGCTTATC ATACCCCTCT TGCCTTGCAC CCCATATGGT 121 CTTCCCAGAG TGAGCTCATC CACCTCGTCA TGCCTGACTC GACGTTCA H55617 SOURCE human clone=C22_757 primer=T3 library=Chromosome 22 exon Trofatter, et al., Genome Res. 5 (3): 214-224 (1995) SEQ ID No. 14 1 GATGGTCGAG TACTCCCTGG ACCTTCAGAA CATCAACCTG TCAGCCATCC GCACCGTGCG 61 CGTCCTGAGG CCCCTCAAAG CCATCAACCG CGTGCCCA H55223 SOURCE human clone=C22_204 primer=T3 library=Chromosome 22 exon Trofatter, et al, Genome Res. 5 (3): 214-224 (1995) SEQ ID No. 15 1 CATGCTGGTG ATCCTGCTGA ACTGCGTGAC ACTTGGCATG TACCAGCCGT GCGACGACAT 61 GGACTGCCTG TCCGACCGCT GCAAGATCCT GCAG H55544 SOURCE human clone=C22_651 primer=T3 library=Chromosome 22 exon Trofatter. et al. Genome Res. 5 (3): 214-224 (1995) SEQ ID No. 16 1 GTATCTCTGG TTACTTTAGT AGCCAACACT CTTGGCTACT CAGACCTTGG TCCCATTAAA 61 TCCCTGCGAA CCTTGAGAGC ACTAAGACCT CTAAGAGCTT TGTCTAGATT TGAAGGAATG 121 AGG F07776 SOURCE human. Submitted (19-JAN-1995) Genethon, B.P. 60, 91002 Evry Cedex France and Genetique Moleculaire et Biologie du deveioppement, CNRS UPR420 B.P. 8, 94801 Villejuif Cedex France E-mail: genexpress@genethon.fr SEQ ID No. 17 1 TTCTCTCCAT TGTAGG AATG TTTCTGGCTG AACTGATAGA AAAGTATTTT GTGTGCCCTA 61 CCCTGTTNCG AGTGATCCGT CTTGCCAGGA TTGGCCGAAT CCTACGTCTG ATCAAAGGAG 121 CAAAGGGGAT CCGCACGCTG CTCTTTGCTT TGATGATGTC CCTTCCTGCG TTGTTTAACA 181 TCGGNCTCCT TCTTTTCCTG GTCATGTTCA TCTACGNCAT CTTTGGGATG TCCAATTTTG 241 CCTATGTTAA GAGGGAAGTT GGGATCGATG ACATGTTNAN CTTTGAGACC TTTGGCAACA 301 GCATGATCTG CCTGTTCCAA ATTACAACCT CTGCTGGCTG GGA A search of the Sanger Genome Sequencing Center (Cambridge, U.K.) and the Washington University Genome Sequencing Center (St. Louis. MO) sequences in progress revealed a Bacterial Artificial Chromosome (BAC) sequence (bK206c7) that contained matches to the C. elegans cosmid open reading frame, C54D2.5, and to the four human chromosome 22 ESTs, H55225, H55617, H55223,H55544. The C. elegans C54D2.5 cosmid sequence and the human EST sequences were then used to compare the translation of the bK206c7 BAC genomic sequence in all 6 reading frames. The analysis was performed using the graphical program Dotter ( Eric Sohnhammer. NCBI). The analysis revealed a series of poten t ial coding regions on one strand of the bK206c7 BAC sequence. These were subsequently translated in all 3 reading frames and the potential splice junctions identified. The t ranslated sequence of this longer DNA fragment which is part of the human α„ subunit gene is given by Seq. ID No. 18. Using the sequence information from the five ESTs, a full length gene can be recovered using any of several techniques. Polynucieotide probes having a sequence which corresponds to or hybridizes with the EST sequences or a distinctive portion thereof (for example oligonucieotide probes having a length of 18 to 100 nucleotides) can be used to probe a human cDNA library for identification of the full length DNA encoding the α„ and α, H subunits. The process of identifying cDNAs of interest using defined probes is well known in the art and is, for example, described in International Patent Publication No. WO95/04144, which is incorporated herein by reference. This process generally involves screening bacterial hosts (e.g. E. coli) harboring the library plasmids or infected with recombinant lambda phage with labeled probes, e.g. radiolabeled with 3 P, and selection of colonies or phage which bind the labeled probe. Each selected colony or phage is grown up, and the plasmids are recovered. Human cDNAs are recovered from t he plasmids by restriction digestion, or can be amplified, for example by PCR. The recovered cDNA can be sequenced, and the position of the calcium channel subunit-encoding region further refined, although neither process is not necessary to the further use of the cDNA to produce cell lines expressing the novel calcium channel subunits. Longer portions of DNA-encoding the novel calcium channel subunits of the invention can also be recovered by PCR cloning techniques using primers corresponding to or based upon the EST sequences. Using this technique to identify relevant sequences within a human brain total RNA preparation confirmed that the novel α„ calcium channel subunit is present in human brain. Subcloning of the 567 nt PCR product and subsequent sequencing thereof showed that this product corresponds to the derived sequence form the bK206c7 BAC genomic sequence. The nucleotide sequence is given as SEQ ID No. 19. The same experiment was performed using a rat brain RNA preparation and resulted in recovery of a substantially identical PCR product. (SEQ ID. NO. 20). The protein encoded by the rat PCR product is 96% identical to the human PCR product. These sequences, which presumably encode a partial subunit can be used as a basis for constructing full length human or rat α„ clones. Briefly, the subcloned α u PCR product is radiolabeled by random hexamer priming according to standard methods (See, Sambrook , J., Fritsch, E.F. and Maniatis, T. (1989) Molecular Cloning, A Laboratory Manual. Cold Spring Harbor Press) and used to screen commercial human brain cDNA libraries (Stratagene. La Jolla, CA). The screening of cDNA libraries follows standard methods and includes such protocols as infecting bacteria with recombinant lambda phage, immobilizing lambda DNA to nitrocellulose filters and screening under medium hybridization stringency conditions with radiolabeled probe. cDNA clones homologous to the probe are identified by autoradiography. Positive clones are purified by sequential rounds of screening. Following this protocol, most purified cDNA's are likely to be partial sequence clones due the nature of the cDNA library synthesis. Full length clones are constructed from cDNA's which overlap in DNA sequence. Restriction enzyme sites which overlap between cDNAs are used to ligate the individual cDNA's to generate a full-length cDNA. For subsequent heterologous expression, the full-length cDNA is subcloned directly into an appropriate vertebrate expression vector, such as pcDNA-3 (Invitrogen, San Diego, CA) in which expression of the cDNA is under the control of a promoter such as the CMV major intermediate early promoter/enhancer. Other suitable expression vectors include, for example, pMT2, pRC/CMV, pcDNA3.1 and pCEP4. Once the full length cDNA is cloned into an expression vector, the vector is then transfected into a host cell for expression. Suitable host cells include Xenopus oocytes or mammalian cells such as human embryonic kidney cells as described in International Patent Publication No. WO 96/39512 which is incorporated herein by reference and Ltk cells as described in US Patent No. 5,386.025 which is incorporated herein by reference. Transfection into host cells may be accomplished by microinjection, lipofection, glycerol shock, electroporation calcium phosphate or particle-mediated gene transfer. The vector may also be transfected into host cells to provide coexpression of the novel α, subunits with a β and or an α,ό subunit. The resulting cell lines expressing functional calcium channels including the novel α, subunits of the invention can be used test compounds for pharmacological activity with respect to these calcium channels. Thus, the cell lines are useful for screening compounds for pharmaceutical utility. Such screening can be carried out using several available methods for evaluation of the interaction, if any, between the test compound and the calcium channel. One such method involves the binding of radiolabeled agents that interact with the calcium channel and subsequent analysis of equilibrium binding measurements including but not limited to. on rates, off rates, K d values and competitive binding by other molecules. Another such method involves the screening for the effects of compounds by electrophysioiogical assay whereby individual cells are impaled with a microelectrode and currents through the calcium channel are recorded before and after application of the compound of interest. Another method, high-throughput spectrophotometric assay, utilizes the loading the cell lines with a fluorescent dye sensitive to intracellular calcium concentration and subsequent examination of the effects of compounds on the ability of depolarization by potassium chloride or other means to alter intracellular calcium levels. Compounds to be tested as agonists or antagonists of the novel α,, and α, H calcium channel subunits are combined with cells that are stably or transiently transformed with a DNA sequence encoding the α„ or α, H calcium channel subunits of the invention and monitored using one of these techniques. DNA fragments with sequences given by SEQ ID Nos. 13-19 may also be used for mapping the distribution of α„ and α 1H calcium channel subunits within a tissue sample. This method follows normal histological procedures using a nucleic acid probe, and generally involves the steps of exposing the tissue to a reagent comprising a directly or indirectly detectable label coupled to a selected DNA fragment, and detecting reagent that has bound to the tissue. Suitable labels include fluorescent labels, enzyme labels, chromophores and radio-labels. EXAMPLE 1 In order to isolate novel human calcium channel α, subunits using standard molecular cloning protocols, synthetic DNA probes are prepared, radiolabeled with 32 P and utilized to screen human cDNA libraries commercially available in lambda phage vectors (Stratagene. La Jolla. CA) based on the human DNA sequences for H55225, H55617, H55223, H55544 and F07776. DNA fragments with the sequence of sequence ID NOs 18 and 19 may also be used for this purpose. Positive phage are purified through several rounds of screening involving immobilizing the phage DNA on nitrocellulose filters, hybridizing with the radiolabeled probe, washing off of excess probe and then selection of clones by autoradiography. Clones identified by this approach are expected to be partial length clones due to the nature of cDNA library synthesis and several rounds of screening for each calcium channel type may be necessary to obtain full-length clones. To characterize the clones, double stranded plasmid DNA is prepared from the identified clones and the sequences are determined using "S dATP, Sequenase and standard gel electrophoresis methods. Regions of similarity and regions of overlap are determined by comparison of each cDNA sequence. Full-length clones are constructed by ligating overlapping cDNA fragments together at common restriction enzyme sites. The full-length clones are subsequently inserted into vectors suitable for expression in vertebrate cells (e.g. pMT2, pRC/CMV, pcDNA3.1, pCEP4, pREP7) by Iigation into restriction sites in the vector polylinker region which is downstream of the promoter used to direct cDNA expression. DNA encoding the novel calcium channels can be stably or transiently introduced into eukaryotic cells (e.g. human embryonic kidney, mouse L cells, C hinese hamster ovary, etc) by any number of available standard methods. Stable transfection is achieved by growing the cells under conditions that promote growth of cells expressing a marker gene which is contained in the expression vector (e.g. dihydrofolate reductase, ' thymidine kinase. or the like). The heterologous DNA encoding the human calcium channel may be integrated into the genome or may be maintained as an episomal element. Expression of the human calcium channel in transfected ceils may monitored by any number of techniques, including Northern blot for RNA analysis. Southern blot for cDNA detection, electrophysioiogical assay for calcium channel function, the binding of radiolabeled agents thought to interact with the calcium channel, and fluorescent assay of dyes sensitive to intracellular calcium concentration. EXAMPLE 2 Heterologous Expression of Human α,, Calcium Channels in Cells A. Transient Transfection in Mammalian Cells Host cells, such as human embryonic kidney ceils, HEK 293 (ATCC# CRL 1573) are grown in standard DMEM medium supplemented with 2 mM glutamine and 10% fetal bovine serum. HEK 293 cells are transfected by a standard calcium-phosphate-DNA co- precipitation method using the full-lenngth human α„ calcium channel cDNA in a vertebrate expression vector (for example see Current protocols in Molecular Biology). The human α„ calcium channel cDNA may be transfected alone or in combination with other cloned subunits for mammalian calcium channels, such as α2δ and β subunits, and also with clones for marker proteins such the jellyfish green fluorescent protein. Electrophysioiogical Recording: After an incubation period of from 24 to 72 hrs the culture medium is removed and replaced with external recording solution (see below). Whole cell patch clamp experiments are performed using an Axopatch 200B amplifier (Axon Instruments, Burlingame. CA) linked to an IBM compatible personal computer equipped with pCLAMP software. Microelectrodes are filled with 3 M CsCl and have typical resistances from 0.5 to 2.5 M_. The external recording solution is 20 mM BaCl 2 1 mM MgCl 2 , 10 mM HEPES, 40 mM TEAC1, 10 mM Glucose, 65 mM CsCl, (pH 7.2). The internal pipette solution is 105 mM CsCl, 25 mM TEAC1, 1 mM CaCl 2 , 11 mM EGTA, 10 mM HEPES (pH 7.2). Currents are typically elicited from a holding potential of -100 mV to various test potentials. Data are filtered at 1 kHz and recorded directly on the harddrive of a personal computer. Leak subtraction is carried out on-line using a standard P/5 protocol. Currents are analyzed using pCLAMP versions 5.5 and 6.0. Macroscopic current-voltage relations are fitted with the equation I = { l/(l+exp(-(V, n -V h )/S)} x G - (V ra -E rev ), where V m is the test potential. V,, is the voltage at which half of the channels are activated, and S reflects the steepness of the activation curve and is an indication of the effective gating charge movement. Inactivation curves are normalized to 1 and fitted with I = (1/1 + exp ((V m -V h )/S) with V m being the holding potential. Single channel recordings are performed in the cell-attached mode with the following pipette solution (in mM): 100 BaCl,, 10 HEPES, pH 7.4 and bath solution: 100 KC1, 10 EGTA. 2 MgCl,, 10 HEPES, pH 7.4. B. Transient Transfection in Xenopus Oocvtes Stage V and VI Xenopus oocytes are prepared as described by Dascal et al (1986), Expression and modulation of voltage-gated calcium channels after RNA injection into Xenopus oocytes. Science 231 :1147-1150. After enzymatic dissociation with coUagenase, oocytes nuclei are microinjected with the human α„ calcium channel cDNA expression vector construct (approximately 10 ng DNA per nucleus) using a Drummond nanoject apparatus. The human α„ calcium channel may be injected alone, or in combination with other mammalian calcium channel subunit cDNAs, such as the α2-δ and βlb subunits. After incubation from 48 to 96 hrs macroscopic currents are recorded using a standard two microelectrode voltage-clamp (Axoclamp 2A, Axon Instruments, Burlingame. CA) in a bathing medium containing (in mM): 40 Ba(OH) 2ι , 25 TEA-OH, 25 NaOH, 2 CsOH, 5 HEPES (pH titrated to 7.3 with methan-sulfonic acid). Pipettes of typical resistance ranging from 0.5 to 1.5 m_ are filled with 2.8M CsCl, 0.2M CsOH, lOmM HEPES, lOmM BAPTA free acid. Endogenous Ca (and Ba) -activated Cl currents are suppressed by systematically injecting 10-30 nl of a solution containing lOOmM BAPTA-free acid, lOmM HEPES (pH titrated to 7.2 with CsOH) using a third pipette connected to a pneumatic injector. Leak currents and capacitive transients are subtracted using a standard P/5 procedure. EXAMPLE 3 Construction of Stable Cell Lines Expressing Human α,. Calcium Channels Mammalian cell lines stably expressing human α„ calcium channels are constructed by transfecting the α„ calcium channel cDNA into mammalian cells such as HEK 293 and selecting for antibiotic resistance encoded for by an expression vector. Briefly, the full-length human α„ calcium channel cDNA subcloned into a vertebrate expression vector with a selectable marker, such as the pcDNA3 (InvitroGen, San Diego, CA), is transfected into HEK 293 cells by calcium phosphate coprecipitation or lipofection or electroporation or other method according to well known procedures (Methods in Enzymology, Volume 185, Gene Expression Technology (1990) Edited by Goeddel, D.V.). The human α„ calcium channel may be transfected alone, or in combination with other mammalian calcium channel subunit cDNAs, such as the α2-δ and β lb subunits, either in a similar expression vector or other type of vector using different selectable markers. After incubation for 2 days in nonselective conditions, the medium is supplemented with Geneticin (G418) at a concentration of between 600 to 800 ug/ml. After 3 to 4 weeks in this medium, cells which are resistant to G418 are visible and can be cloned as isolated colonies using standard cloning rings. After growing up each isolated colony to confluency to establish cell lines, the expression of human α„ calcium channels can be determined at with standard gene expression methods such as Northern blotting, RNase protection and reverse-transcriptase PCR. The functional detection of human α„ calcium channels in stably transfected cells can be examined electrophysiologically, such as by whole patch clamp or single channel analysis (see above). Other means of detecting functional calcium channels include the use of radiolabeled 3 Ca uptake, fluorescence spectroscopy using calcium sensitive dyes such as FURA-2, and the binding or displacement of radiolabeled ligands that interact with the calcium channel. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Snutch. Terry P. Baillie, David L. (ii) TITLE OF INVENTION: Novel Human Calcium Channels and Related Probes. Cell Lines and Methods (iii) NUMBER OF SEQUENCES: 20 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: (B) STREET: (C) CITY: (D) STATE: (E) COUNTRY: (F) ZIP: (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Diskette. 3.50 inch, 1.44 Kb storage (B) COMPUTER: IBM Compatible (C) OPERATING SYSTEM: MS DOS 6.0 (D) SOFTWARE: WordPerfect (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Larson, Marina T. (B) REGISTRATION NUMBER: 32038 (C) REFERENCE/DOCKET NUMBER: NMED.P-001-US (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (914) 245-3252 (B) TELEFAX: (914) 962-4330 (2) INFORMATION FOR SEQ ID NO: 1 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (vi) ORIGINAL SOURCE: (A) ORGANISM: rat (ix) FEATURE: oligonucieotide probe for locating calcium channel genes (xi)SEQUENCE DESCRIPTION: SEQ ID NO:l: GTCAAAACTC AGGCCTTCTA CTGG 24 - 20 - (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (vi) ORIGINAL SOURCE: (A) ORGANISM: rat (ix) FEATURE: oligonucieotide probe for locating calcium channel genes (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 2: AACGTGTTCT TGGCTATCGC GGTG 24 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (vi) ORIGINAL SOURCE: (A) ORGANISM: rat (ix) FEATURE: oligonucieotide probe for locating calcium channel genes (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 3: GTGAAAGCAC AGAGCTTCTA CTGG 24 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (vi) ORIGINAL SOURCE: (A) ORGANISM: rat (ix) FEATURE: oligonucieotide probe for locating calcium channel genes (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 4: AACGTTTTCT TGGCCATTGC TGTG 24 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (vi) ORIGINAL SOURCE: (A) ORGANISM: rat (ix) FEATURE: oligonucieotide probe for locating calcium channel genes (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 5: GTTAAATCCA ACGTCTTCTA CTGG 28 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (vi) ORIGINAL SOURCE: (A) ORGANISM: rat (ix) FEATURE: oligonucieotide probe for locating calcium channel genes (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 6: AATGTGTTCT TGGCCATTGC GGTG 24 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (vi) ORIGINAL SOURCE: (A) ORGANISM: rat - 22 - (ix) FEATURE: oligonucieotide probe for locating calcium channel genes (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 7: GTGAAGTCTG TCACGTTTTA CTGG 24 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (vi) ORIGINAL SOURCE: (A) ORGANISM: rat (ix) FEATURE: oligonucieotide probe for locating calcium channel genes (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 8: AAGCTCTTCT TGGCCATTGC TGTA 24 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (vi) ORIGINAL SOURCE: (A) ORGANISM: rat (ix) FEATURE: oligonucieotide probe for locating calcium channel genes (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 9: GTCAAGTCGC AAGTGTTCTA CTGG 24 (2) INFORMAΗON FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (vi) ORIGINAL SOURCE: (A) ORGANISM: rat (ix) FEATURE: oligonucieotide probe for locating calcium channel genes (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 10: AATGTATTCT TGGCTATCGC TGTG 24 (2) INFORMATION FOR SEQ ID NO: 11 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (vi) ORIGINAL SOURCE: (A) ORGANISM: rat (ix) FEATURE: oligonucieotide probe for locating calcium channel genes (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 11: ATCTAYGCYR TSATYGGSAT G 21 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (vi) ORIGINAL SOURCE: (A) ORGANISM: rat (ix) FEATURE: oligonucieotide probe for locating calcium channel genes (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 12: ATGGACAAYT TYGASTAYTC 20 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 168 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (vi) ORIGINAL SOURCE: (A) ORGANISM: human (ix) FEATURE: expressed sequence tag H55225 (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 13: GTGATCACTC TGGAAGGCTG GGTGGAGATC ATGTACTACG TGATGGATGC TCACTCCTTC 60 TACAACTTCA TCTACTTCAT CCTGCTTATC ATACCCCTCT TGCCTTGCAC CCCATATGGT 120 CTTCCCAGAG TGAGCTCATC CACCTCGTCA TGCCTGACTC GACGTTCA 168 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 98 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (vi) ORIGINAL SOURCE: (A) ORGANISM: human (ix) FEATURE: expressed sequence tag H55617 (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 14: GATGGTCGAG TACTCCCTGG ACCTTCAGAA CATCAACCTG TCAGCCATCC GCACCGTGCG 60 CGTCCTGAGG CCCCTCAAAG CCATCAACCG CGTGCCCA 98 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 94 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (vi) ORIGINAL SOURCE: (A) ORGANISM: human (ix) FEATURE: expressed sequence tag H55223 (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 15: CATGCTGGTG ATCCTGCTGA ACTGCGTGAC ACTTGGCATG TACCAGCCGT GCGACGACAT 60 GGACTGCCTG TCCGACCGCT GCAAGATCCT GCAG 94 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 123 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (vi) ORIGINAL SOURCE: (A) ORGANISM: human (ix) FEATURE: expressed sequence tag H55544 (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 16: GTATCTCTGG TTACTTTAGT AGCCAACACT CTTGGCTACT CAGACCTTGG TCCCATTAAA 60 TCCCTGCGAA CCTTGAGAGC ACTAAGACCT CTAAGAGCTT TGTCTAGATT TGAAGGAATG 120 AGG 123 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 343 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (iQMOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (vi) ORIGINAL SOURCE: (A) ORGANISM: human (ix) FEATURE: expressed sequence tag F07776 (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 17: TTCTCTCCAT TGTAGGAATG TTTCTGGCTG AACTGATAGA AAAGTATTTT GTGTGCCCTA 60 CCCTGTTNCG AGTGATCCGT CTTGCCAGGA TTGGCCGAAT CCTACGTCTG ATCAAAGOAG 120 CAAAGGGGAT CCGCACGCTG CTCTTTGCTT TGATGATGTC CCTTCCTGCG TTGTTTAACA 180 TCGGNCTCCT TCTTTTCCTG GTCATGTTCA TCTACQNCAT CTTTGGOATG TCCAATTTTG 240 CCTATGTTAA GAGGGAAGTT GGGATCGATG ACATGTTNAN CTTTGAGACC TTTGGCAACA 300 GCATGATCTG CCTGTTCCAA ATTACAACCT CTGCTGGCTG GGA 3*3 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5562 (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (vi) ORIGINAL SOURCE: (A) ORGANISM: human (ix) FEATURE: human alpha-I partial sequence from BAC bK206c7 (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 18: ATG TTT TTC GTC TCA GCC AAT CCC TGG GTG AGT TTC ACC AGT TTT GAT TTA AAC 54 Met Phe Phe Val Ser Ala Asn Pro Trp Val Ser Phe Thr Ser Phe Asp Leu Asn GTG GCC AAT ATG GAC AAC TTC TTC GCC CCC GTT TTC ACC ATG GGC AAA TAT TAT 108 Val Ala Asn Met Asp Asn Phe Phe Ala Pro Val Phe Thr Met Gly Lys Tyr Tyr ACG CAA GGC GAC AAG GTG CTG ATG CCG CTG GCG ATT CAG GCT CTG AAA CAG CTG 162 Thr Gin Gly Asp Lys Val Leu Met Pro Leu Ala He Gin Ala Leu Lys Gin Leu ATG TTC AAA TTG GTG GCC ACT GTT GCT CGA ACA CAT GCT ACA CCG TCA CAC ATC 206 Met Phe Lys Leu Val Ala Thr Val Ala Arg Thr His Ala Thr Pro Ser His He ACG GGT GGT CCT GGA ACA GGG ATG CAC ACG GGC ACC TTC CAG GAA GGA GCT GAG 270 Thr Gly Gly Pro Gly Thr Gly Met His Thr Gly Thr Phe Gin Glu Gly Ala Glu CCT GGT TCA TCT CAG CAC CCT GAG GCA CAG GCC ACG TAT ACA GCA GGG TGC ACC 324 Pro Gly Ser Ser Gin His Pro Glu Ala Gin Ala Thr Tyr Thr Ala Gly Cys Thr CCA GCC CCC ACG GGC GAT CCC ACC TGC TGC TTT GTC CTT GAC TTG GTG TGC ACG 378 Pro Ala Pro Thr Gly Asp Pro Thr Cys Cys Phe Val Leu Asp Leu Val Cys Thr TGG TTT GAA TGT GTC AGC ATG CTG GTG ATC CTG CTG AAC TGC GTG ACA CTT GGC 432 Trp Phe Glu Cys Val Ser Met Leu Val He Leu Leu Asn Cys Val Thr Leu Gly ATG TAC CAG CCG TGC GAC GAC ATG GAC TGC CTG TCC GAC CGC TGC AAG ATC CTG 486 Met Tyr Gin Pro Cys Asp Asp Met Asp Cys Leu Ser Asp Arg Cys Lys He Leu CAG GTC TTT GAT GAC TTC ATC TTT ATC TTC TTT GCC ATG GAG ATG GTG CTC AAG 540 Gin Val Phe Asp Asp Phe He Phe He Phe Phe Ala Met Glu Met Val Leu Lys ATG GTG GCC CTG GGG ATT TTT GGC AAG AAG TGC TAC CTC GGG GAC ACA TGG AAC 594 Met Val Ala Leu Gly lie Phe Gly Lys Lys Cys Tyr Leu Gly Asp Thr Trp Asn CGC CTG GAT TTC TTC ATC GTC ATG GCA GGC AAC ATC AAC CTG TCA GCC ATC CGC 648 Arg Leu Asp Phe Phe He Val Met Ala Gly Asn He Asn Leu Ser Ala He Arg ACC GTG CGC GTC CTG AGG CCC CTC AAA GCC ATC AAC CGC GTG CCC AGT ATG CGG 702 Thr Val Arg Val Leu Arg Pro Leu Lys Ala He Asn Arg Val Pro Ser Met Arg ATC CTG GTG AAC CTG CTC CTG GAC ACA CTG CCC ATG CTG GGG AAT GTC CTG CTG 756 He Leu Val Asn Leu Leu Leu Asp Thr Leu Pro Met Leu Gly Asn Val Leu Leu CTC TGC TTC TTT GTC TTC TTC ATC TTT GGC ATC ATA GGT GTG CAG CTC TGG GCG 810 Leu Cys Phe Phe Val Phe Phe He Phe Gly He He Gly Val Gin Leu Trp Ala GGC CTG CTG CGT AAC CGC TGC TTC CTG GAG GAG AAC TTC ACC ATA CAA GGG GAT 864 Gly Leu Leu Arg Asn Arg Cys Phe Leu Glu Glu Asn Phe Thr He Gin Gly Asp GTG GCC TTG CCC CCA TAC TAC CAG CCG GAG GAG GAT GAT GAG ATG CCC TTC ATC 918 Val Ala Leu Pro Pro Tyr Tyr Gin Pro Glu Glu Asp Asp Glu Met Pro Phe He TQC TCC CTG TCG GGC GAC AAT GGG ATA ATG GGC TGC CAT GAG ATC CCC CCG CTC 972 Cyβ Ser Leu Ser Gly Asp Asn Gly He Met Gly Cys His Glu He Pro Pro Leu AAQ GAG CAG GGC CGT GAG TGC TGC CTG TCC AAG GAC GAC GTC TAC GAC TTT GGG 1026 Lye Glu Gin Gly Arg Glu Cys Cys Leu Ser Lys Asp Asp Val Tyr Asp Phe Gly GCG GGG CGC CAG GAC CTC AAT GCC AGC GGC CTC TGT GTC AAC TGG AAC CGT TAC 108O Ala Gly Arg Gin Asp Leu Asn Ala Ser Gly Leu Cys Val Asn Trp Asn Arg Tyr TAC AAT GTG TGC CGC ACG GGC AGC GCC AAC CCC CAC AAG GGT GCC ATC AAC TTT 1134 Tyr Asn Val Cys Arg Thr Gly Ser Ala Asn Pro His Lys Gly Ala He Asn Phe GAC AAC ATC GGT TAT GCT TGG ATT GTC ATC TTC CAG GTG ATC ACT CTG GAA GGC 1188 Asp Asn He Gly Tyr Ala Trp He Val He Phe Gin Val He Thr Leu Glu Gly TGG GTG GAG ATC ATG TAC TAC GTG ATG GAT GCT CAC TCC TTC TAC AAC TTC ATC 1242 Trp Val Glu He Met Tyr Tyr Val Met Asp Ala His Ser Phe Tyr Asn Phe He TAC TTC ATC CTG CTT ATC ATA AGT GAG CTC ATC CAC CTC GTC ATG CCT GAC TGC 1296 Tyr Phe He Leu Leu He He Ser Glu Leu He His Leu Val Met Pro Asp Cys AGC TTC AGC ACA GCA CAG TCC CCA AAA TGT CAA GGT GAT TCA CTC CCA GGA GTC 1350 Ser Phe Ser Thr Ala Gin Ser Pro Lys Cys Gin Gly Asp Ser Leu Pro Gly Val GCT GCT GAA TCC CTG CTG CTG CGA GAC TCT AGC TCC TCA GTC ATC ACT GAT GAG 1404 Ala Ala Glu Ser Leu Leu Leu Arg Asp Ser Ser Ser Ser V al He Thr Asp Glu GCT GCA GCC ATG GAG AAC CTC CTG GCG GGC ACC TCC AAG GGG GAT GAA AGC TAT 1 458 Ala Ala Ala Met Glu Asn Leu Leu Ala Gly Thr Ser Lys Gly Asp Glu Ser Tyr CTG CTC AGG CTG GCC GGC AGC CAA GTT CAC TCC CAG GCT CAG CAA ATG CTG GGG 1512 Leu Leu Arg Leu Ala Gly Ser Gin Val His Ser Gin Ala Gin Gin Met Leu Gly AGG GGG CTG GGC CCT GAA AGC CTG GAA ACT GGA GAG GAG CCC CAC TCG TGG AGC 1566 Arg Gly Leu Gly Pro Glu Ser Leu Glu Thr Gly Glu Glu Pro His Ser Trp Ser CCT CGG GCC ACA AGG AGA TGG GAT CCC CAA TGC CAA CCA GGG CAG CCT CTC CCC 1620 Pro Arg Ala Thr Arg Arg Trp Asp Pro Gin Cys Gin Pro Gly Gin Pro Leu Pro CTT CAT TTC ATG CAA GCA CAG GTG GGC TCC TTC TTC ATG ATC AAC CTG TGC CTC 1674 Leu His Phe Met Gin Ala Gin Val Gly Ser Phe Phe Met He Asn Leu Cys Leu GTT GTC ATA GCG ACC CAG TTC TCG GAG ACC AAG CAA CGG GAG CAC CGG CTG ATG 1728 Val Val He Ala Thr Gin Phe Ser Glu Thr Lys Gin Arg Glu His Arg Leu Met CTG GAG CAG CGG CAG CGC TAC CTG TCC TCC AGC ACG GTG GCC AGC TAC GCC GAG 1782 Leu Glu Gin Arg Gin Arg Tyr Leu Ser Ser Ser Thr Val Ala Ser Tyr Ala Glu CCT GGC GAC TGC TAC GAG GAG ATC TTC CAG TAT GTC TGC CAC ATC CTG CGC AAG 1836 Pro Gly Asp Cys Tyr Glu Glu He Phe Gin Tyr Val Cys His He Leu Arg Lys Ala L^s A rα f* _? ^ ∞C "= ™ CAG GCC CTG °» *∞ CGG CGC CAG GCC 1890 Ala Lys Arg Arg Ala Leu Gly Leu Tyr Gin Ala Leu Gin Ser Arg Arg Gin Ala til Giv Pro __° A I C o ∞ G ? C CCC GCC ** CCT GGG CCC «C GCC AAG GAG CCC 1944 Leu Gly Pro Glu Ala Pro Ala Pro Ala Lys Pro Gly Pro His Ala Lys Glu Pro Arg £ϊ ϊvr Pro ° ϊ ' l ^ GAA T ° G ATT CTT GGG AGG CAA GCA GAA GAA 1998 Arg H i s Tyr Pro Leu Thr Val Trp Glu Ser He Leu Gly Arg Gin Ala Glu Glu CCvyss TThhrr ILIeu AArrσg A Ϊ?la A _l,a° Ala His P C r ∞ o T Se°r C T Se° G r G GGT GCC ∞ <*T CCA GGC GTG 2049 ly Ala Ser His Pro Gly Val GGC TCG GAG GAG GCC CCA GAG CTG TGC CCG CAA CAT AGC CCC CTG GAT GCG ACG 2106 Gly Ser Glu Glu Ala Pro Glu Leu Cys Pro Gin His Ser Pro Leu Asp Ala Thr CCC CAC ACC CTG GTG CAG CCC ATC CCC GCC ACG CTG GCT TCC GAT CCC GCC AGC 2160 Pro His Thr Leu Val Gin Pro He Pro Ala Thr Leu Ala Ser Asp Pro Ala Ser TGC CCT TGC TGC CAG CAT GAG GAC GGC CGG CGG CCC TCG GGC CTG GGC AGC ACC 2214 Cys Pro Cys Cys Gin His Glu Asp Gly Arg Arg Pro Ser Gly Leu Gly Ser Thr GAC TCG GGC CAG GAG GGC TCG GGC TCC GGG AGC TCC GCT GGT GGC GAG GAC GAG 2268 Asp Ser Gly Gin Glu Gly Ser Gly Ser Gly Ser Ser Ala Gly Gly Glu Asp Glu GCG GAT GGG GAC GGG GCC CGG AGC AGC GAG GAC GGA GCC TCC TCA GAA CTG GGG 2322 Ala Asp Gly Asp Gly Ala Arg Ser Ser Glu Asp Gly Ala Ser Ser Glu Leu Gly AAG GAG GAG GAG GAG GAG GAG CAG GCG GAT GGG GCG GTC TGG CTG TGC GGG GAT 2376 Lys Glu Glu Glu Glu Glu Glu Gin Ala Asp Gly Ala Val Trp Leu Cys Gly Asp GTG TGG CGG GAG ACG CGA GCC AAG CTG CGC GGC ATC GTG GAC AGC AAG TAC TTC 2430 Val Trp Arg Glu Thr Arg Ala Lys Leu Arg Gly He Val Asp Ser Lys Tyr Phe AAC CGG GGC ATC ATG ATG GCC ATC CTG GTC AAC ACC GTC AGC ATG GGC ATC GAG 2484 Aβn Arg Gly He Met Met Ala He Leu Val Asn Thr Val Ser Met Gly He Glu CAC CAC GAG CAG GCC AGT GCA GCG CAG CCG GGC CGG GCC TGC GGG AGA GGA CAA 2538 His His Glu Gin Ala Ser Ala Ala Gin Pro Gly Arg Ala Cys Gly Arg Gly Gin AAT CCA GAC CTT TGC ATG ACC CTC AAG GCC CCT TGT CTC TGT CAC AAC GTC CCT 2592 Aβn Pro Asp Leu Cys Met Thr Leu Lys Ala Pro Cys Leu Cys His Asn Val Pro TCA CCA GGC CAG GGT GTC CTG TCC CAT CCA GTG ACT CCA CCC CAT ACA GCC CCA 2646 Ser Pro Gly Gin Gly Val Leu Ser His Pro Val Thr Pro Pro His Thr Ala Pro TGG CGC ATG GAG ACA GGA AAG CAG GGA CAC GGA TGT GAA GAA GGA CCA GGA CAA 2700 Trp Arg Met Glu Thr Gly Lys Gin Gly His Gly Cys Glu Glu Gly Pro Gly Gin CGA AGC AGT GAC ATG TTT GCC CTG GAG ATG ATC CTG AAG CTG GCT GCA TTT GGG 2754 Arg Ser Ser Asp Met Phe Ala Leu Glu Met He Leu Lys Leu Ala Ala Phe Gly CTC TTC GAC TAC CTG CGT AAC CCC TAC AAC ATC T T C GAC AGC ATC A TT GTC ATC 2808 --u Ph e A sp T yr L eu Arg Asn Pro τ yr Asn He Ph e A sp S er He He V al He ATC AGC ATC TGG GAG ATC GTG GGG CAG GCG GAC G GT GGG CTG TCG GTG C T G CGG 286 2 He S er He T rp Gl u He Val Gly Gin Ala Asp G ly G ly L eu S er V al L eu A rg ACC TTC CGG CTG CTG CGC GTG CTG AAA CTG GTG C GC T T C ATG CCT GCC CTG CGG 29 1 6 T hr Ph e A rg L eu L eu Arg Val Leu Lys Leu Val A rg P he M e t P ro A la L eu A rg CGC CAG CTC GTG GTG CTC ATG AAG ACC ATG GAC AAC GTG GCC ACC T T C TGC ATG 2970 A rg G in L eu V al V a l Leu Met Lys Thr Met Asp A sn V al A la T hr Ph e C ys M et CTG CTC ATG CTC TTC AT C TTC ATC TTC AGC ATC C TT GGG ATG CAT A TT TTT GGC 30 2 4 L eu L eu M e t L eu Ph e l ie Phe He Phe Ser He L eu G ly M et H is He P he G ly II _^ PH C C C CGC ACG GAC ACT GGA GAC ACG GTG CCC GAC AGG AAG AAC 3078 C ys L ys P he S er L eu Arg Thr Asp Thr Gly Asp T hr V al P ro A sp A rg Lys Asn TT C G A C TCC CTG CTG TG G GCC ATC GTC ACT GTG T T C CAG ATC CTC A CC CAG GAG 313 2 Phe A sp S er L eu L eu Trp Ala He Val Thr Val P he G in He L eu Thr G in G lu A ϋ β £p s T rpϋ ϊ A* ssn V a c l Γ V aTl L CT eu C T T A y C r *A*s*n G G G ly C A M T e G t A GC la C τ S e cc r A T h CT r τ S e cτ r c P c r c o τ T σ r σ p A GC la C τ S e cc r 3 «6 SLeuu I T yr H P hZe u VT alι A GC la C C L T eu C A M T e G t A Th CC r T P T he C G GG l C y *Asn T T A y T r G V T a G l C L T eu G T P TheC A AAsnC LCTeuG LCTeuG 3240 S? Ala T1 C f™ G GGC TTC " GCG ∞ GTG ACT ™ TT G GC A G A G 3 294 V al A la He L eu V al G lu Gly Phe Gin Ala Glu Val Thr V al V al Leu Ala Glu ϊ G lϋu S A la P P rroo GG ?l C y C L T e G u A CG r A g *L*ys» A Th CT r G G G l G y A CG r A g G G G l G y A A G rg G β «ly G ∞ly LTeuG A G AspT 33 48 G lvy G G ly G G llvy L L T e G u ^ G in i P he Lys C L T eu T C L T e A u A GC l A a G G G ly C ^ A sn L CT e A u T S C e C r Leu Lys G <*lu» G°∞ly 3402 V V aall AAlla S A sIp o G lu V a?l ϊ G fly A GA sp C A GC la C A**sn A CG rg C T Se C r C T T A y C r T S e CG r A GA sp C G«l β u A«spC G C Ain G A S G erC 3 456 I S err S S eerr A A ^snn Hϊe r Gl u r Gl u Ph*e A **sp* ^Lys ^Leu G ∞in G GA l A u G G G ly C G L T eu A A sp G A S e G r S ∞er G ∞ly 3 510 GAT CCC AAG CTC TCC CCA ATC CCC ATG ACC CCC AAT GGG CAC CTG GAC CCC AGT 3564 Asp Pro Lys Leu Cys Pro He Pro Met Thr Pro Asn Gly His Leu Asp Pro Ser CTC CCA CTG GGT GGG CAC CTA GGT CCT GCT GGG GCT GCG GGA CCT GCC CCC CGA 3618 Leu Pro Leu Gly Gly His Leu Gly Pro Ala Gly Ala Ala Gly Pro Ala Pro Arg CTC TCA CTG CAG CCG GAC CCC ATG CTG GTG GCC CTG GGC TCC CGA AAG AGC AGC 3672 Leu Ser Leu Gin Pro Asp Pro Met Leu Val Ala Leu Gly Ser Arg Lys Ser Ser GTC ATG TCT CTA GGG AGG ATG AGC TAT GAC CAG CGC TCC CTG GTG GGT GGT CTT 3726 Val Met Ser Leu Gly Arg Met Ser Tyr Asp Gin Arg Ser Leu Val Gly Gly Leu AGA GCC ACA GCG GGG GTG CAG GCT GCC TTT GGG CAC CTG GTG CCC CAG CCG TGG 3780 Arg Ala Thr Ala Gly Val Gin Ala Ala Phe Gly His Leu Val Pro Gin Pro Trp GTG TGC CTG TGG GGC GCT GAC CCG AAC GGG AAC TCC TTC CAG TCC AGC TCC CGG 3834 Val Cys Leu Trp Gly Ala Asp Pro Asn Gly Aβn Ser Phe Gin Ser Ser Ser Arg AGC TCC TAC TAC GGG CCA TGG GGC CGC AGC GCG GCC TGG GCC AGC CGT CGC TCC 3888 Ser Ser Tyr Tyr Gly Pro Trp Gly Arg Ser Ala Ala Trp Ala Ser Arg Arg Ser AGC TGG AAC AGC CTC AAG CAC AAG CCG CCG TCG GCG GAG CAT GAG TCC CTG CTC 3942 Ser Trp Asn Ser Leu Lys His Lys Pro Pro Ser Ala Glu His Glu Ser Leu Leu TCT GCG GAG CGC GGC GGC GGC GCC CGG GTC TGC GAG GTT GCC GCG GAC GAG GGG 3996 Ser Ala Glu Arg Gly Gly Gly Ala Arg Val Cys Glu Val Ala Ala Asp Glu Gly CCG CCG CGG GCC GCA CCC CTG CAC ACC CCA CAC GCC CAC CAC GTT CAT CAC GGG 4050 Pro Pro Arg Ala Ala Pro Leu His Thr Pro His Ala His His Val His His Gly CCC CAT CTG GCG CAC CGC CAC CGC CAC CAC CGC CGG ACG CTG TCC CTC GAC AAC 4104 Pro His Leu Ala His Arg His Arg His His Arg Arg Thr Leu Ser Leu Asp Asn AGG GAC TCG GTG GAC CTG GCC GAG CTG GTG CCC GCG GTG GGC GCC CAC CCC CGG 4158 Arg Asp Ser Val Asp Leu Ala Glu Leu Val Pro Ala Val Gly Ala His Pro Arg GCC GCC TGG AGG GCG GCA GGC CCG GCC CCC GGG CAT GAG GAC TGC AAT GGC AGG 4212 Ala Ala Trp Arg Ala Ala Gly Pro Ala Pro Gly His Glu Asp Cys Asn Gly Arg ATG CCC AGC ATC GCC AAA GAC GTC TTC ACC AAG ATG GGC GAC CGC GGG GAT CGC 4266 Met Pro Ser lie Ala Lys Asp Val Phe Thr Lys Met Gly Asp Arg Gly Asp Arg GGG GAG GAT GAG GAG GAA ATC GAC TAC GTG AGT GGG GGC GGG GCC GAA GGG GAC 4320 Gly Glu Asp Glu Glu Glu He Asp Tyr Val Ser Gly Gly Gly Ala Glu Gly Asp CTG ACC CTG TGC TTC CGC GTC CGC AAG ATG ATC GAC GTC TAT AAG CCC GAC TGG 4374 Leu Thr Leu Cys Phe Arg Val Arg Lys Met He Asp Val Tyr Lys Pro Asp Trp TGC GAG GTC CGC GAA GAC TGG TCT GTC TAC CTC TTC TCT CCC GAG AAC AGG CTC 4428 Cys Glu Val Arg Glu Asp Trp Ser Val Tyr Leu Phe Ser Pro Glu Asn Arg Leu AGG GAT CTG GGC TGG GTA AGC CTC GAG TGC CAG GGA AAG GTG GGT GAC CTC GTG 4482 Arg Asp Leu Gly Trp Val Ser Leu Glu Cys Gin Gly Lys Val Gly Asp Leu Val GTG TGG GTG TAT GGT CAG AGG AGG CAG CGC CAG ACC ATT ATT GCC CAC AAA CTC 4536 Val Trp al Tyr Gly Gin Arg Arg Gin Arg Gin Thr He He Ala His Lys Leu TTC GAC TAC GTC GTC CTG GCC TTC ATC TTT CTC AAC TGC ATC ACC ATC GCC CTG 4590 Phe Asp Tyr Val Val Leu Ala Phe He Phe Leu Asn Cys He Thr He Ala Leu GAG CGG CCT CAG ATC GAG GCC GGC AGC ACC GAA CGC ATC TTT CTC ACC GTG TCC 4644 Glu Arg Pro Gin He Glu Ala Gly Ser Thr Glu Arg He Phe Leu Thr Val Ser AAC TAC ATC TTC ACG GCC ATC TTC GTG GGC GAG ATG ACA TTG AAG GTA GTC TCG 4698 Asn Tyr He Phe Thr Ala He Phe Val Gly Glu Met Thr Leu Lys Val Val Ser CTG GGC CTG TAC TTC GGC GAG CAG GCG TAC CTA CGC AGC AGC TGG AAC GTG CTG 4752 Leu Gly Leu Tyr Phe Gly Glu Gin Ala Tyr Leu Arg Ser Ser Trp Asn Val Leu GAT GGC TTT CTT GTC TTC GTG TCC ATC ATC GAC ATC GTG GTG TCC CTG GCC TCA 4806 Asp Gly Phe Leu Val Phe Val Ser He He Asp He Val Val Ser Leu Ala Ser GCC GGG GGA GCC AAG ATC TTG GGG GTC CTC CGA GTC TTG CGG CTC CTG CGC ACC 4860 Ala Gly Gly Ala Lys He Leu Gly Val Leu Arg Val Leu Arg Leu Leu Arg Thr CTA CGC CCC CTG CGT GTC ATC AGC CGG GCG CCG GGC CTG AAG CTG GTG GTG GAG 4914 Leu Arg Pro Leu Arg Val He Ser Arg Ala Pro Gly Leu Lys Leu Val Val Glu ACA CTC ATC TCC TCC CTC AAG CCC ATC GGC AAC ATC GTG CTC ATC TGC TGT GCC 496 β Thr Leu He Ser Ser Leu Lys Pro He Gly Asn He Val Leu He Cys Cys Ala TTC TTC ATC ATC TTT GGC ATC CTG GGA GTG CAG CTC TTC AAG GGC AAG TTC TAC 5022 Phe Phe He He Phe Gly He Leu Gly Val Gin Leu Phe Lys Gly Lys Phe Tyr CAC TGT CTG GGC GTG GAC ACC CGC AAC ATC ACC AAC CGC TCG GAC TGC ATG GCC 5076 His Cys Leu Gly Val Asp Thr Arg Asn He Thr Asn Arg Ser Asp Cys Met Ala GCC AAC TAC CGC TGG GTC CAT CAC AAA TAC AAC TTC GAC AAC CTG GGC CAG GCT 5130 Ala Asn Tyr Arg Trp Val His His Lys Tyr Asn Phe Asp Asn Leu Gly Gin Ala CTG ATG TCC CTC TTT GTC CTG GCA TCC AAG GAT GGT TGG GTG AAC ATC ATG TAC 5185 Leu Met Ser Leu Phe Val Leu Ala Ser Lys Asp Gly Trp Val Asn He Met Tyr AAT GGA CTG GAT GCT GTT GCT GTG GAC CAG CAG CCT GTG ACC AAC CAC AAC CCC 5238 Asn Gly Leu Asp Ala Val Ala Val Asp Gin Gin Pro Val Thr Asn His Asn Pro TGG ATG CTG CTG TAC TTC ATC TCC TTC CTG CTC ATC GTC AGC TTC TTT GTG CTC 5292 Trp Met Leu Leu Tyr Phe He Ser Phe Leu Leu He Val Ser Phe Phe Val Leu AAC ATG TTT GTG GGT GTC GTG GTG GAG AAC TTC CAC AAG TGC CGG CAG CAC CAG 5346 A β n Met Phe Val Gly Val Val Val Glu Asn Phe His Lys Cys Arg Gin His Gin GAG GCT GAA GAG GCA CGG CGG CGT GAG GAG AAG CGG CTG CGG CGC CTG GAG AAG 5400 Glu Ala Glu Glu Ala Arg Arg Arg Glu Glu Lys Arg Leu Arg Arg Leu Glu Lys AAG CGC CGG AAG GCC CAG CGG CTG CCC TAC TAT GCC ACC TAT TGT CAC ACC CGG 5454 Lys Arg Arg Lys Ala Gin Arg Leu Pro Tyr Tyr Ala Thr Tyr Cys His Thr Arg CTG CTC ATC CAC TCC ATG TGC ACC AGC CAC TAC CTG GAC ATC TTC ATC ACC TTC 5508 Leu Leu He His Ser Met Cys Thr Ser His Tyr Leu Asp He Phe He Thr Phe ATC ATC TGC CTC AAC GTG GTC ACC ATG TCC CTG GAG CAC TAC AAT CAG CCC ACG 5562 He He Cys Leu Asn Val Val Thr Met Ser Leu Glu His Tyr Asn Gin Pro Thr (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 567 (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii)MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (vi) ORIGINAL SOURCE: (A) ORGANISM: human (ix) FEATURE: human alpha-I partial sequence (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 19: ATG CGG ATC CTG GTG AAC CTG CTC CTG GAC ACA CTG CCC ATG CTG GGG AAT GTC 54 Met Arg He Leu Val Asn Leu Leu Leu Asp Thr Leu Pro Met Leu Gly Asn Val CTG CTG CTC TGC TTC TTT GTC TTC TTC ACC TTT GGC ATC ATA GGT GTG CAG CTC 108 Leu Leu Leu Cys Phe Phe Val Phe Phe Thr Phe Gly He He Gly Val Gin Leu TGG GCG GGC CTG CTG CGT AAC CGC TGC TTC CTG GAG GAG AAC TTC ACC ATA CAA 162 Trp Ala Gly Leu Leu Arg Asn Arg Cys Phe Leu Glu Glu Asn Phe Thr He Gin GGG GAT GTG GCC TTG CCC CCA TAC TAC CAG CCG GAG GAG GAT GAT GAG ATG CCC 216 Gly Asp Val Ala Leu Pro Pro Tyr Tyr Gin Pro Glu Glu Asp Asp Glu Met Pro TTC ATC TGC TCC CTG TCG GGC GAC AAT GGG ATA ATG GGC TGC CAT GAG ATC CCC 270 Phe He Cys Ser Leu Ser Gly Asp Asn Gly He Met Gly Cys Hie Glu He Pro CCG CTC AAG GAG CAG GGC CGT GAG TGC TGC CTG TCC AAG GAC GAC GTC TAC GAC 324 Pro Leu Lys Glu Gin Gly Arg Glu Cys Cys Leu Ser Lys Asp Asp Val Tyr Asp TTT GGG GCG GGG CGC CAG GAC CTC AAT GCC AGC GGC CTC TGT GTC AAC TGG AAC 378 Phe Gly Ala Gly Arg Gin Asp Leu Asn Ala Ser Gly Leu Cys Val Aβn Trp Aβn CGT TAC TAC AAT GTG TGC CGC ACG GGC AGC GCC AAC CCC CAC AAG GGT GCC ATC 432 Arg Tyr Tyr Asn Val Cys Arg Thr Gly Ser Ala Asn Pro His Lye Gly Ala He AGC TTT GAC AAC ATC GGT TAT GCT TGG ATT GTC ATC TTC CAG GTG ATC ACT CTG 486 Ser Phe Asp Asn He Gly Tyr Ala Trp He Val He Phe Gin Val He Thr Leu GAA GGC TGG GTG GCG ATC ATG TAC TAC GTG ATG GAT GCT CTC TCC TTC TAC AAC 540 Glu Gly Trp Val Ala He Met Tyr Tyr Val Met Asp Ala Leu Ser Phe Tyr Asn TTC GTC TAC TTC ATC CTG CTT ATC ATA 567 Phe Val Tyr Phe He Leu Leu He He (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 567 (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii)MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: no (iv) ANTI-SENSE: no (vi) ORIGINAL SOURCE: (A) ORGANISM: rat (ix) FEATURE: rat alpha-I partial sequence (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 20: ATG CGG ATC CTG GTG AAC CTG CTG CTC GAC ACG CTG CCC ATG CTG GGG AAC GTG 54 Met Arg He Leu Val Asn Leu Leu Leu Asp Thr Leu Pro Met Leu Gly Asn Val CTC CTG CTC TGT TTC TTC GTC TTC TTC ATC TTC GGC ATC ATT GGC GTG CAG CTC 108 Lβu Leu Leu Cys Phe Phe Val Phe Phe He Phe Gly He He Gly Val Gin Leu TGO GCA GGC CTG CTA CGG AAC CGC TGC TTC CTG GAA GAA AAC TTC ACC ATA CAA 162 Trp Ala Gly Leu Leu Arg Asn Arg Cys Phe Leu Glu Glu Asn Phe Thr He Gin GGG GAT GTG GCC CTG CCC CCT TAT TAC CAA CCA GAG GAG GAT GAC GAG ATG CCC 216 Gly Asp Val Ala Leu Pro Pro Tyr Tyr Gin Pro Glu Glu Asp Asp Glu Met Pro TTT ATC TGC TCC CTG ACT GGG GAC AAT GGC ATC ATG GGC TGC CAC GAG ATC CCC 270 Phe He Cys Ser Leu Thr Gly Asp Asn Gly He Met Gly Cys His Glu He Pro CCA CTG AAG GAG CAG GGC CGG GAA TGC TGC CTG TCC AAA GAT GAT GTG TAT GAC 324 Pro Leu Lys Glu Gin Gly Arg Glu Cys Cys Leu Ser Lys Asp Asp Val Tyr Asp TTC GGG GCG GGG CGC CAG GAC CTC AAC GCC AGC GGT CTG TGC GTC AAC TGG AAC 378 Phe Gly Ala Gly Arg Gin Asp Leu Asn Ala Ser Gly Leu Cye Val Aβn Trp A β n CGC TAC TAC AAC GTC TGC CGC ACG GGC AAC GCC AAC CCT CAC AAG GGC GCC ATC 432 Arg Tyr Tyr Asn Val Cys Arg Thr Gly Asn Ala Asn Pro His Lys Gly Ala He AAC TTT GAC AAC ATT GGC TAT GCC TGG ATT GTG ATT TTC CAG GTG ATC ACT CTG 486 Asn Phe Asp Asn He Gly Tyr Ala Trp He Val He Phe Gin Val He Thr Leu GAA GGC TGG GTG GAG ATC ATG TAC TAT GTG ATG GAC GCA CAT TCT TTC TAC AAC 540 Glu Gly Trp Val Glu He Met Tyr Tyr Val Met Asp Ala His Ser Phe Tyr Asn TTC ATC TAC TTC ATC CTG CTT ATC ATA 567 Phe He Tyr Phe He Leu Leu He He

Claims: CLAIMS 1. An isolated DNA fragment comprising a sequence of nucleotides that encodes a calcium channel, wherein the sequence of nucleotides is selected from sequences of nucleotides encoding a protein including the sequence of amino acids set forth in SEQ ID. No. 19, and sequences of nucleotides that hybridize under non-stringent conditions to DNA encoding a protein including the sequence set forth in SEQ ID No. 19. 2. The DNA fragment of Claim 1, wherein the sequence of nucleotides is selected from sequences of nucleotides encoding a protein including the sequence of amino acids set forth in SEQ ID. No. 18, and sequences of nucleotides that hybridize under non-stringent conditions to DNA encoding a protein including the sequence set forth in SEQ ID No. 18. 3. The DNA fragment of Claim 1 or 2, wherein the calcium channel is a human neuronal calcium channel. 4. An isolated DNA fragment comprising a sequence of nucleotides that encodes a human calcium channel subunit, wherein the sequence of nucleotides is selected from sequences of nucleotides including the sequence set forth in SEQ ID No. 17. 5. A vertebrate expression vector containing the DNA fragment of any of Claims 1 to 6. A eukaryotic cell transiently or stably transformed with the vertebrate expression vector of Claim 5, said cell expressing the calcium channel encoded by the DNA fragment 7. A eukaryotic cell transiently or stably transformed with a heterologous DNA fragment according to any of Claims 1 to 4, said cell expressing the calcium channel encoded by the DNA fragment. 8. The eukaryotic cell of claim 6 or 7. wherein the ceil is further transformed with and expresses an α2δ or a β calcium channel subunit. or both. 9. A method for the production of the α-,, protein of an animal cell calcium channel comprising, culturing the cell of Claim 6 or 7 under conditions whereby the DNA encoding the calcium channel subunit is expressed and the α-,, subunit is produced. 10. A process for producing the eukaryotic cell that is transiently or stably transformed and expresses a calcium channel, comprising the step of introducing RNA or DNA having a sequence selected from among sequences that encode a protein including the sequence of amino acids set forth in SEQ ID. No. 19, and sequences of nucleotides that hybridize under non-stringent conditions to DNA encoding a protein including the sequence set forth in SEQ ID No. 19 and RNA or DNA encoding an α2δ or β calcium channel subunit into a ceil. 11. A method of identifying compounds capable of acting as agonists or antagonists for the α-[, calcium channel, comprising contacting a cell according to claim 6 or 7 with an agent to be tested, and evaluating the interaction, if any, between the agent to be tested and the calcium channel. 12. An isolated DNA fragment having the sequence given by SEQ ID No. 19. 13. A method for mapping the distribution of calcium channel subunits within a tissue sample comprising the steps of exposing the tissue to a reagent comprising a directly or indirectly detectable label coupled to a DNA fragment comprising a sequence selected from among those sequences given by SEQ ID Nos. 13-20, and detecting reagent that has bound to the tissue.

Inventors: BAILLIE DAVID L, SNUTCH TERRY P, BAILLIE, DAVID, L., SNUTCH, TERRY, P.
Applicants: NEUROMED TECH INC, NEUROMED TECHNOLOGIES INC.
Application year: 1998
Main classification: C12N15
IPC codes: C07K14, C12N1, C12N5, C12N15, C12P21, C12Q1, G01N33